Sulaco, I agree with the exception that any further weakness in the share price presents a strong temptation to add. Of course, each of us has to look at our risk tolerance and all that, but the ever increasing MOS numbers might just translate into share price movement in the next few weeks or months(!).
Let's not forget the government. What does a drug extending the lives of many do to those entitlement payout curves. Very expensive to society. How much does cancer deaths save in benefit payouts. How does that affect the need to absorb this drug?